Comparative chart of single and combination treatment options indicating which lipids can be targeted for dyslipidemias.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
The FDA is working in close collaboration with global regulatory partners to evaluate the controls in place and publish guidance on preventing unacceptable levels of nitrosamine in drugs.
Population-based cohort study demonstrated associations between many site-specific cancers and the development of CVDs.
[Cancer Management and Research] This retrospective study investigated the likelihood of CVD-related chronic conditions being diagnosed in survivors of nonmetastatic CRC and of effective management of these conditions over 12 months following CRC diagnosis.
Exposure to ≥250 mg/m² doxorubicin-equivalent anthracycline chemo tied to risk for CVD, heart failure.
Seniors with preexisting cardiovascular diseases have higher risk for short-term mortality with AA, ENZ.
Researchers compared the development of specific CVD risk factors in postmenopausal women who survived breast cancer and women without history of breast cancer.